http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2384763-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4ae0884e2839c2d44e5bed7e35951b2a |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-475 |
filingDate | 2006-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8bb221a1f46518ea36f29f8b1b7eac24 |
publicationDate | 2011-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-2384763-A1 |
titleOfInvention | A peptide ligand to impair cancer cell migration |
abstract | Loss of Wnt-5a protein expression in breast carcinoma patients is associated with a shorter recurrence-free survival as well as increased motility in mammary cell lines. Based on sequence analysis of Wnt-5a 13 peptide fragments were identified and investigated for their ability to mimic the effects of the Wnt-5 a protein on mammary cell adhesion and motility. Two of these peptides significantly increased adhesion and impaired the motility of non-tumourigenic brest cancer cell lines, both low in engogenous Wnt-5a expression. To identify the shortest possible peptide that still had an anti-motile effect, sequential deletions of two amino acids from the N-terminal side of the shorter of these two peptides were performed. The effect on tumour cell adhesion was gradually lost, and when only 6 amino acids remained the effect was not detectabel. However, formylation of the N-terminal methionine of this hexapeptide restored its effect on adhesion and reduced tumour cell motility. The novel formyl-Met-Asp-Gly-Cys-Glu-Leu peptide ligand can serve as a lead substance for anti-metastatic treatment in the <<50 % of human breast cancers where the endogenous expression of Wnt-5a is reduced. |
priorityDate | 2005-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 186.